Why did STAB stock surge pre-market today?

The pre-market surge ties to renewed attention on SEC filings and market-data coverage, combined with thin liquidity and low float. Small trades can move price sharply in microcap stocks like Statera Biopharma.

What is Meyka AI’s grade and forecast for STAB stock?

Meyka AI rates STAB with a score out of 100: 64.13 (Grade B, Suggestion: HOLD). The model projects a yearly price near 0.04309 USD; forecasts are projections and not guarantees.

What are the main risks when trading STAB stock?

Main risks include extreme volatility, thin volume, negative operating cash flow per share of -0.80, a low current ratio of 0.37, and binary clinical or financing outcomes that can wipe value quickly.

Does Statera Biopharma pay dividends or have positive earnings?

No. Statera Biopharma reports negative EPS (**-2.36**) and no dividend history. The company is clinical-stage and prioritizes R&D financing over payouts.

US Stocks

STAB (Statera Biopharma) NASDAQ +200.00% pre-market 09 Jan 2026: monitor catalysts

ByDanny Kontos January 9, 2026January 9, 2026

STAB stock is the pre-market top gainer after a 200.00% move, trading on the NASDAQ in the United States ahead of the session on 09 Jan 2026. Statera Biopharma, Inc. (STAB) shows a traded volume near 700.00 and a tiny market cap of 7142.00 USD, with the price at roughly 3.00e-04 USD. The surge follows renewed attention to SEC filings and recent coverage; we break down drivers, financials, technicals and a model forecast from Meyka AI to frame the risk-reward for investors.